Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyashita, Yosuke, Ko, Ryo, Shimada, Naoko, Mitsuishi, Yoichiro, Miura, Keita, Matsumoto, Naohisa, Asao, Tetsuhiko, Shukuya, Takehito, Shibayama, Rina, Koyama, Ryo, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862784/
https://www.ncbi.nlm.nih.gov/pubmed/33219754
http://dx.doi.org/10.1111/1759-7714.13742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862784/
https://www.ncbi.nlm.nih.gov/pubmed/33219754
http://dx.doi.org/10.1111/1759-7714.13742

Ejemplares similares